| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LCN1 |
| Uniprot No | P31025 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-176aa |
| 氨基酸序列 | MKPLLLAVSLGLIAALQAHHLLASDEEIQDVSGTWYLKAMTVDREFPEMN LESVTPMTLTTLEGGNLEAKVTMLISGRCQEVKAVLEKTDEPGKYTADGG KHVAYIIRSHVKDHYIFYCEGELHGKPVRGVKLVGRDPKNNLEALEDFEK AAGARGLSTESILIPRQSETCSPGSD |
| 预测分子量 | 45 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于LCN1重组蛋白的3篇参考文献及其摘要内容：
1. **文献名称**: *"Recombinant human lipocalin-1 (LCN1) inhibits bacterial biofilm formation through iron sequestration"*
**作者**: Fluckinger M, et al.
**摘要**: 该研究报道了通过大肠杆菌表达系统成功制备重组人源LCN1蛋白，并证明其通过螯合铁离子抑制铜绿假单胞菌等病原菌生物膜的形成，揭示了其在抗感染治疗中的潜在应用。
2. **文献名称**: *"Structural and functional characterization of recombinant tear lipocalin (LCN1) expressed in yeast"*
**作者**: Glasgow BJ, et al.
**摘要**: 作者利用酵母表达系统重组表达LCN1蛋白，通过X射线晶体学解析其三维结构，并验证其结合疏水分子(如视黄醇)的能力，强调了LCN1在泪液稳定性和眼表保护中的生理作用。
3. **文献名称**: *"LCN1 as a biomarker for dry eye disease: Production and validation of a recombinant protein-based diagnostic assay"*
**作者**: Smith TJ, et al.
**摘要**: 研究开发了一种基于重组LCN1蛋白的ELISA检测方法，用于定量泪液中的LCN1水平，发现其在干眼症患者中显著降低，提示其作为疾病诊断标志物的潜力。
(注：以上文献为示例，实际引用需根据具体研究核实。)
**Background of LCN1 Recombinant Protein**
Lipocalin-1 (LCN1), also known as tear lipocalin or von Ebner’s gland protein, is a small secretory protein belonging to the lipocalin superfamily. It is naturally expressed in tear fluid, saliva, and other mucosal secretions, where it plays a critical role in binding and transporting hydrophobic molecules, such as lipids, steroids, and microbial components. Structurally, LCN1 features a characteristic eight-stranded β-barrel fold, forming a hydrophobic pocket that facilitates ligand interactions. This multifunctional protein contributes to ocular surface homeostasis, antimicrobial defense, and anti-inflammatory responses, making it essential for maintaining healthy mucosal environments.
Recombinant LCN1 is produced using biotechnological platforms, such as bacterial or mammalian expression systems, to achieve high-purity, scalable protein yields. Its recombinant form retains the native protein’s functional properties, including ligand-binding capacity and stability in diverse physiological conditions. Research on LCN1 has expanded due to its therapeutic potential, particularly in treating dry eye syndrome, where it supplements natural tear film components. Additionally, its ability to bind pathogenic molecules positions it as a candidate for developing anti-infective agents or drug delivery systems.
Studies also explore LCN1’s role in disease biomarkers and cellular signaling pathways. Despite progress, challenges remain in optimizing production methods and fully elucidating its molecular interactions. Overall, LCN1 recombinant protein serves as a versatile tool in both basic research and clinical applications, bridging insights into mucosal immunity and therapeutic innovation.
×
